Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Low Float!!!
WSRC My PINK pick for 2023
Got filled @.09...ASK still .0919
I have an order in for 5K @ .09 and they won't fill it. .088 x .0919
... while KYNC is a $15MM microcap, which according to BBG has an even more ridiculous 399% SI/Float ratio.
2 weeks would be even better. The 6 month time frame seems to be when most of the accumulation occurs.
$BABL Very interesting chart since mid Sept. These things don't wake up like that for no reason. It seems like things start happening 6 months prior to a larger move. So that would put us mid March.
Should see $2+ this week with a little more volume.
Head fake...watch all of these gains fade after the first hour...IMO
Wasn't he the guy on Martin? LoL I wonder if you can get Viggle points for watching it?
I have 10K for sale @ $0.26 Please take my shares of this undervalued gem. lol
From the 10-K for NEMUS BIOSCIENCE, INC. - 27-Mar-2015
Annual Report: Results of Operations
For the years ended December 31, 2014 and 2013
Revenues
To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.
Operating Expenses
For the year ended December 31, 2014, our total operating expenses were $2,731,661 as compared to $120,403 for the year ended December 31, 2013. The increase in operating expenses was due primarily to an increase in research and development costs and consulting and professional fees in the year ended December 31, 2014, as discussed below.
Research and development. Research and development expenses for the year ended December 31, 2014 were $227,500 which consisted of license fees payable to UM to obtain rights to the following three cannabinoid extracts for the purposes of FDA approval and commercialization:
1) UM 1490 - transmucosal delivery of cannabinoids
2) UM 5070 - treatment for methicillin-resistant Staphylococcus aureus infections
3) UM 8790 - ocular delivery of cannabinoids
For the year ended December 31, 2013, our research and development expenses were $0.
General and administrative. General and administrative expenses for the year ended December 31, 2014 were $2,504,161 which primarily consisted of consulting fees and professional fees associated with our costs of becoming a public company. By comparison, our general and administrative expenses for year ended December 31, 2013 were $120,403 which primarily consisted of consulting fees paid to an entity owned by Reg Lapham, our former officer and director.
Net Loss
For the year ended December 31, 2014, we had a net loss of $2,734,166, as compared to a net loss of $120,403 for the year ended December 31, 2013. We expect to incur net losses for the foreseeable future.
Table of Contents
Liquidity and Capital Resources
We had cash and cash equivalents of $207,330 as of December 31, 2014, as compared to $0 as of December 31, 2013. In January 2015, we raised an additional $724,989 to be utilized to fund ongoing operations. We anticipate that we will continue to incur net losses into the foreseeable future as we continue to advance and develop a number of potential drug candidates into preclinical development activities and expand our corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that we will not have sufficient funds to meet our obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to our ability to continue as a going concern.
We have been, and intend to continue, working toward identifying and obtaining new sources of financing. No assurances can be given that we will be successful in obtaining additional financing in the future. Any future financing that we may obtain may cause significant dilution to existing stockholders. Any debt financing or other financing of securities senior to common stock that we are able to obtain will likely include financial and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a negative impact on our business, prospects, financial condition, results of operations and cash flows.
If adequate funds are not available, we may be required to delay, scale back or eliminate portions of our operations or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain of our assets. Accordingly, the inability to obtain such financing could result in a significant loss of ownership and/or control of our assets and could also adversely affect our ability to fund our continued operations and our expansion efforts.
During the next twelve months, we expect to incur significant research and development expenses with respect to our products. The majority of our research and development activity is focused on development of potential drug candidates and preclinical trials.
We also expect to incur significant legal and accounting costs in connection with becoming a public company. We expect those fees will be significant and will continue to impact our liquidity. Those fees will be higher as our business volume and activity increases.
We anticipate that we will need to hire additional employees or independent contractors for our new laboratory at UM. We also anticipate that we will need to purchase or lease additional equipment for the Company's headquarters and laboratory facilities.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.
Key areas of resistance are at .64 & .73 IMO Looking for a strong close today, which should continue this uptrend next week.
If you think a cash (non-margin) account will protect you from your broker lending out your shares, you're mistaken. Ask yourself why it takes 3 days for settlement, if everything is done electronically?
Glad it closed above .18 yesterday. Get through these .18s and the next level of resistance is .20 and then .25. A close above either would turns those into support. This would definitely be confirmation of a reversal. Let's see what today brings us.
Last update...I received his email. And in it, I'm going to have to quote directly from it..."PNTV’s expects its new proprietary enterprise platform, NextGenTV, to transform New Media practices." Pretty bold statement considering they couldn't even send the attachments in .PDF format. I got 3 .WORD documents. Yeah, .WORD docs I'm still shaking my head.
Seems like it, plenty of Red Flags here...
They just returned my call... got my contact info from a Small Cap list. Trying to drum up interest in the company. Mentioned pending litigation with Comcast. I asked him what the AS is, he fumbled for a second and said he thought it was 200m, with the OS around 175M. Something that caught my attention is that he said he wasn't use to that many shares. He then asked if he could email me some info about the company and their last few PRs. I can't wait to see what he sends me...
Called the main #, Ext. 102 is investor relations. Waited on hold for a minute and then got sent to VM. I left a message. I'll report again if I get a call back from them. I just wanted to see if anyone else has been called by their IR department.
Have they called you? I'll return his call and report back...
Which is even more weird because I don't own any of their stock, have never owned it. After I looked up the ticker and saw what it was trading at.....They Must Be Looking For $$$$. BUYER BEWARE!!!
Does anyone know who Richatd Engle is from Players Network? I received a phone message from him. Which is weird because it is my # from 3 years ago..
I'm still waiting for that close above .18. Still waiting....
BL-1040 (Out-Licensed to Bellerophon Therapeutics)
Indication: Acute Myocardial Infarction
Mode of Action: Temporary mechanical support
Stage of development: CE Mark registration trial
Patent status: Patents granted or pending worldwide, 20-year expiration in 2029 (in US); 2024 (rest of world)
BL-1040 Overview
BL-1040 represents a breakthrough approach to supporting cardiac tissue damaged as the result of ischemia. The liquid BL-1040 is administered via intra-coronary injection and, on contact with damaged cardiac tissue, undergoes a transition from liquid to gel. This gel provides mechanical support allowing the damaged tissue to heal as a more compact, less dilated and "tighter" scar, which results in improved long-term cardiac function. BL-1040 resorbs naturally and is excreted from the body within six weeks of injection.
BL-1040 Clinical Data
BioLineRx has completed a phase I/II pilot clinical trial designed to assess the safety and feasibility of BL-1040 in patients who have experienced a significant AMI. The trial was conducted at 9 sites in Europe. An Independent Safety Monitoring Board (ISMB) reviewed the data from the study and concluded that the treatment is safe and clinical development of the device may continue.
BL-1040 (now called "Bioabsorbable Cardiac Matrix” or "BCM” by Bellerophon) is currently undergoing the PRESERVATION I clinical trial, which aims to evaluate the safety and effectiveness of BL-1040 in the prevention of ventricular remodeling and congestive heart failure when administered following AMI. This trial is a double-blind, placebo-controlled, CE Mark registration trial in up to 306 patients following AMI at over 80 sites in nine countries, and includes a six-month follow-up period.
Pre-Clinical Data
BL-1040 efficacy has been extensively studied in different models. The results of these studies show that BL-1040, administered at up to 7 days post AMI, improves survival, prevents the dilation of left ventricular end systolic and diastolic volume, prevents fractional shortening deterioration and improves mitral regurgitation. Treatment also minimizes the systolic wall thinning, a finding consistent with the prevention of progressive infarct expansion.
Safety and biocompatibility studies revealed no evidence of local or systemic toxicity at equivalent, and significant, multiples of the anticipated human dosage.
In July 2009, BioLine out-licensed BL-1040 to Bellerophon (f/k/a Ikaria) for continuation of development and commercialization (under the name IK-5001 and/or BCM).
BL-1040 was invented by Prof. Smadar Cohen and Prof. Jonathan Leor. BL-1040 is being developed by BioLineRx Ltd. under a worldwide exclusive license from B.G. Negev Technologies.
For more information: bd@BioLineRx.com
Can $BAA survive $850-$950 gold?
Breakout is immanent. Looking for the big move up next week.
They either meet the listing requirement or get the 6 month extension if they don't. I saw that your alias is fairly recent. Is this your 1st exposure to equities?
After watching this trade all week, the maket has $BAA priced right. As long as gold stays at these levels, $BAA will too. And the lower that gold goes, the higher the risk becomes. It's 2015, not 2011-2012.
IMO, NASDQ gives a 6 month extension on a regular basis. No need to worry about it either way.
Data had to of been leaked. Someone wanted a large amount of shares and wanted to pay as little as possible for them. It seems like they shorted the open hard and it just took out all those stops on the way down. Add in an AF article and it was clear sailing all the way to the closing bell. Reversal in progress...
Did anyone have $CUR on L2 when the market opened this morning?
Closing above .18 tomorrow would make $BAA look even better
Looks like $BLRX did well at the ROTH conference yesterday. Pre-Market volume 100k+ and up 6.8%. Lets see what today brings us.
And here comes the good news. $DARA getting some pre-market volume...let's see what today brings us.
RS again in 90 days? That's just not realistic. Orphan Drug Status for KRN5500, receiving 1.1m worth of waivers for 2012-2014 and the institutional holders. I think we'll be hearing good news way before May. Probably in the next few weeks.
KRN5500....as close to a miracle as you're gonna get...
Anyone having trouble getting orders filled on $AEZS ?
Seems like those millions of shares are already being dumped into the market...
Hmm....quite ironic, a positive PR followed by an endless amount of shares available on the ASK....